FogPharma Stock

fogpharma.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $868.26MM

FogPharma is a clinical-stage biotechnology research company striving to develop HeliconTM peptides, an innovative approach aimed at overcoming current medication limitations and creating drug solutions for all human disease drivers. The Helicons are intended to act similarly to antibodies and be allocated across tissue as they interact with small molecules within the cells, whereas most modern tailored medications have difficulty reaching these target areas. FogPharma was founded in 2016 and is headquartered in Cambridge, Massachusetts.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for FogPharma, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Private Market Pricing DetailsValuation & Financings

FogPharma Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

FogPharma Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
03/01/2024 Series E $145MM $xx.xx $491.9MM Nextech Invest, RA Capital Management, Rock Springs Capital, General Catalyst, Marshall Wace, Samsara Biocapital, Foresite Capital, Symbiosis, Catalio Capital Management, Sixty Degree Capital, Alex Gorsky
Price per Share
$xx.xx
Shares Outstanding
23,281,563
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Nextech Invest, RA Capital Management, Rock Springs Capital, General Catalyst, Marshall Wace, Samsara Biocapital, Foresite Capital, Symbiosis, Catalio Capital Management, Sixty Degree Capital, Alex Gorsky
11/21/2022 Series D $178MM $xx.xx $406.53MM ARCH Venture Partners, Milky Way Investments, Fidelity, VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, T. Rowe Price, Invus, Farallon Capital Management, HBM Healthcare Investments, Casdin Capital, PagsGroup
Price per Share
$xx.xx
Shares Outstanding
16,537,979
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
800.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
ARCH Venture Partners, Milky Way Investments, Fidelity, VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, T. Rowe Price, Invus, Farallon Capital Management, HBM Healthcare Investments, Casdin Capital, PagsGroup
03/01/2021 Series C $107MM $xx.xx $262.08MM VenBio Partners, Cormorant Asset Management, Farallon Capital Management, Invus, GV, 6 Dimensions Capital, Deerfield Management, Blue Pool Capital
Price per Share
$xx.xx
Shares Outstanding
7,384,710
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
800.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
VenBio Partners, Cormorant Asset Management, Farallon Capital Management, Invus, GV, 6 Dimensions Capital, Deerfield Management, Blue Pool Capital
05/16/2018 Series B $65.51MM $xx.xx $131.82MM 6 Dimensions Capital, GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group, Lerrink Partners, Deerfield Management, Boyu Capital, WuXi AppTec Corporate Ventures
Price per Share
$xx.xx
Shares Outstanding
4,658,112
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
800.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
6 Dimensions Capital, GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group, Lerrink Partners, Deerfield Management, Boyu Capital, WuXi AppTec Corporate Ventures
05/25/2016 Series A $11.11MM $xx.xx $37.05MM Deerfield Management
Price per Share
$xx.xx
Shares Outstanding
1,434,062
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
800.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Deerfield Management

FogPharma investors also invested in these private companies

Milky Way Investments Group
Blue Pool Capital
Leerink Partners
Boyu Capital

Leadership & Board

Leadership

Mathai Mammen MD, Ph.D.
Chief Executive Officer & President
Rohin Mhatre Ph.D
Chief Technical Operations Officer
Gregory Miller MPH, MBA
Chief Business Officer
Keith Orford MD
Chief Medical Officer & Executive Vice President of Clinical and Translational Science
Kristen Stants MILR
Chief People Officer

Board

Jeffrey Leerink
Leerink Partners
Krishna Yeshwant MD
GV
Alexis Borisy
Nextech Invest

FogPharma stock FAQs

plusminus

Can you buy FogPharma stock?

As FogPharma is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like FogPharma, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy FogPharma stock?

To invest in a private company like FogPharma through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell FogPharma stock?

Yes, you may sell the FogPharma stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell FogPharma stock?

If you hold private company shares of FogPharma – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your FogPharma on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is FogPharma a public company?

No, FogPharma is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is FogPharma’s stock price?

FogPharma is a privately held company and therefore does not have a public stock price. However, you may access FogPharma private market stock price with Forge Data.
plusminus

What is FogPharma’s stock ticker symbol?

FogPharma does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

FogPharma’s news and media highlights

FogPharma elevated its financing with a series E funding round to continue its cancer pharmaceutical research expansion.
FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.
FogPharma has netted a $178 Million Series D financing to develop Helicon polypeptide therapeutics against hard targets.
/PRNewswire/ -- FogPharma today announced the appointment of Fang Wang, Ph.D., as Vice President of Biology and Nancy Wilker, Ph.D., J.D., as Vice President...
Updated on: Nov 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.